US launches Section 301 probe into Germany's pharmaceutical pricing
In brief
- USTR launched formal Section 301 investigation into Germany's pharmaceutical pricing June 18.
- US alleges German price controls shift R&D costs to American patients and companies.
- Public comment period opens June 25; formal hearing scheduled September 22.
- Favorable ruling could establish template for similar trade actions against other countries.
- Germany contests framing as trade violation, arguing price controls are legitimate health policy.
The allegation
Germany's price controls force American patients and companies to effectively subsidize global drug research and development costs, according to the US Trade Representative's argument. Section 301 gives the USTR authority to investigate foreign trade practices deemed unreasonable, unjustifiable, or discriminatory, and then impose tariffs or other restrictions.
USTR Jamieson Greer is turning that tool toward Berlin. A public comments docket opens on June 25, with a formal public hearing scheduled for September 22. The timing is not coincidental: just two days before the USTR's announcement, on June 16, a group of 23 Senate Republicans sent a letter urging action against foreign drug pricing practices.
Precedent and fallout
The US has wielded Section 301 before. It's the same tool the US famously used against China in 2018 to justify sweeping tariffs on hundreds of billions of dollars in goods. The investigation is also part of a broader wave of 2026 Section 301 actions targeting multiple countries.
If the USTR ultimately finds that Germany's pricing practices harm US commerce, retaliatory tariffs on German pharmaceutical exports are possible. For large-cap US pharmaceutical companies, a favorable ruling might eventually force higher drug prices in Germany and potentially across the EU.
Germany contests the framing. Berlin argues that pharmaceutical price controls are a legitimate exercise of health policy, not a trade violation. From the EU's perspective, regulating drug costs to ensure affordable access for citizens is a sovereign right, not an unreasonable trade barrier. Reframing health policy as a trade dispute sets a troubling precedent that could subordinate public health to commercial interests.
The broader stakes
Germany is reportedly fast-tracking legislation designed to further reduce federal spending on innovative medicines. The country's moves signal that Berlin won't capitulate easily. Still, for many European pharma companies, the US market represents their single largest revenue source, giving Washington real leverage.
If the US successfully uses Section 301 to challenge pharmaceutical pricing policies in Germany, it could establish a template for similar actions against the UK, France, Japan, Canada, and dozens of others. That said, other countries' different trade relationships, legal frameworks, and domestic political constraints may limit how far this precedent travels. Each nation's negotiating position is distinct.
